genome-wide association studies (GWAS) in recent years, and the number of these PCa-risk associated SNPs continues to increase. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Although each of these SNPs is only modestly associated with PCa risk, their cumulative effects strongly increase PCa risk. [15] [16] [17] [18] A potential clinical utility of these PCa risk-associated SNPs is risk stratification for targeted intervention such as PSA screening. 19 With more PCa risk-associated SNPs identified, PCa risk estimated for an individual patient from these evolving sets of SNPs could be different. For a subset of individuals, their risk category (higher or lower based on a cutoff value) could be reclassified. The concern of this risk reclassification was raised from a recent simulation study by Krier et al where the risk category was reclassified in 50% of men when using risk-associated SNPs available by 2007 and 2013 . 20 This level of risk reclassification, if observed in empirical studies, would suggest that it is premature to use currently available risk-associated SNPs for risk assessment. The objective of this current study is to assess the degree and impact of this risk reclassification in an actual study population.
We performed a reclassification analysis on four sets of sequentially identified PCa risk-associated SNPs in a well-defined prospective cohort of patients who were followed for four years for detection of PCa.
2 | METHODS
| Study population
This study included 3239 patients enrolled in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) clinical trial who consented for further genetic studies. This trial examined the effect of dutasteride on PCa development, and has been previously described in detail. 21 Briefly, eligible men (1) had a serum PSA between 2.5-10.0 ng/mL (50-60 years of age) or 3.0-10.0 ng/mL (61-75 years of age) and (2) had undergone one 6-12 core biopsy within 6 months of enrollment and were not diagnosed with PCa.
Participants in this trial were randomized to receive Dutasteride (treatment arm) or to receive a placebo (placebo arm). We utilized the placebo arm (n = 1,654) for the primary analyses, due to the effects of dutasteride on decreasing PCa incidence. The treatment arm (n = 1,585 
| Statistical analysis
In this study, a GRS cutoff value of 1.5 was used for risk stratification; men with GRS <1.5 or ≥1.5 were classified as lower or higher risk, respectively. This cutoff value was chosen because it confers a risk of PCa similar to that of having positive FH (odds ratio of FH for PCa diagnosis was 1.5 in the placebo arm of the REDUCE study). The
Pearson correlation coefficient was used to evaluate the linear correlation between each pair of GRS values. T-tests were used to test the differences in means of normally distributed variables between two groups. For variables that were not normally distributed, two tests were performed: (1) a nonparametric method using the Wilcoxon rank sum test and (2) t-tests for different means between two groups after log-transformation. Differences in binary variables were tested using χ 2 tests. Area under the receiver operating characteristic curve (AUC) was used to evaluate the performance in discriminating two groups of subjects. The difference between two AUCs was tested using Delong's test. 23 The Cochran-Armitage trend test was used to test the difference of detection rates across risk categories.
| RESULTS
The baseline demographic and clinical characteristics of men included in this study, stratified by placebo and treatment arms, are shown (Table 1 Although not every individual SNP was significantly associated with PCa risk (data not shown), combinations of these SNPs, measured by GRS, were strongly associated with PCa susceptibility. In the placebo group, the associations between GRS values calculated from each of the four SNP sets and the detection of PCa were highly significant (all P values < 10 Fig. S1 and Table S3 ).
Multiple GRS values from evolving sets of SNPs, nevertheless, offered a tool for further refining risk prediction. In the placebo arm, when all four sequential GRS values were considered, risk reclassification occurred in 26% of men. The observed detection rates of PCa in the 4-year study period were 20.80%, 29.67%, and 39.26% for men whose GRS values were consistently <1.5, changed between <1.5 and ≥1.5 (reclassified), and were consistently ≥1.5, respectively, P trend = 1.12 × 10 −8 (Table 3 ). In comparison, the detection rates of PCa in men with negative or positive FH were 23.75% and 31.78%, respectively. Comparable findings were observed for the treatment arm ( Supplementary Fig. S1 and Table S3 ).
The performance of multiple GRS values from sequentially discovered SNP sets in refining risk assessment was also supported by the observed detection rate of high-grade PCa (Gleason score ≥7) in the 4-year study period. For example, in the placebo arm, the detection rates of high-grade PCa were 5.60%, 7.71%, and 9.82% for men whose GRS values were consistently <1.5, reclassified (changed between 1.5 and ≥1.5), and were consistently ≥1.5, respectively, P trend = 0.02 (Table 3 ). In comparison, the observed detection rates of high-grade PCa were 6.04% and 9.81% for men with a negative or positive FH, respectively. Again, similar findings were observed for the treatment arm (Supplementary Table S3 ).
Parallel results were found using sRAC and PRS for measuring the cumulative effect of multiple risk-associated SNPs. Mean PRS and sRAC of each SNP set in PCa patients were significantly higher than that of non-PCa patients for each set of SNPs (all P values < 0.05). For discriminating cases from controls at a population level, the performance (AUC) of PRS and GRS were the same and were both better than sRAC for each set of SNPs (Supplementary Table S4 Although there were similarities between the results of this study and Krier et al, several differences were noted. 20 The reclassification rate of PCa risk was higher in the study of Krier et al (50%) than ours (26%). 20 This difference is likely due to a combination of factors, including differences in the SNP sets for risk assessment, estimates of ORs and allele frequencies of SNPs used in calculations, and cutoff values (2.0 vs 1.5). A GRS cutoff value of 1.5
was chosen in our study because it confers a risk of PCa similar to that of having positive FH (odds ratio of FH for PCa diagnosis was 1.5 in the placebo arm of the REDUCE study). However, similar findings were observed when a GRS cutoff value of 2.0 was implemented (Supplementary Table S5 ). The most important difference between the two studies is the availability of follow-up data on observed PCa detection. With the prospective design of our Most of the analyses described in this study were performed separately in the two trial arms. The decision to perform these analyses separately was based on the consideration that PCa detection rate was significantly lower in patients treated with dutasteride. 8 Despite these differences, the key findings from the treatment group were consistent with that of the placebo group.
Several methods are commonly used to measure the cumulative effect of multiple risk-associated SNPs, including sRAC, PRS, and GRS. 18, [24] [25] [26] Although the same conclusion of the study can be made from any of these methods, there are important differences between Therefore, GRS is a better choice for risk assessment at an individual level risk assessment.
Important limitations of the study should be noted. First, considering that all subjects in the REDUCE study were men with initially negative biopsies, caution should be made when we attempt to generalize the current results to the general population. Second, the study was restricted to Caucasian men due to the composition of the REDUCE cohort and the fact that most PCa risk-associated SNPs were discovered and confirmed in this racial group. We hypothesize that major findings derived from Caucasians in the study can be replicated in other racial groups, though this needs to be further tested.
Third, using 1.5 (or 2.0) as cutoff value of GRS might be subjective. As GRS provides population standardized risk assessment, GRS = 1.5 (or 2.0) represents a 1.5-fold (or twofold) increase of risk, while GRS = 0.5 represents a 0.5-fold decrease of risk, comparing to average risk of PCa in general population. 27 These cutoffs were easier to understand and were comparable to FH. On the other hand, our results were consistent at both cutoffs (1.5 and 2.0), suggesting that our conclusions could be applied to a wider range. Fourth, the GRSs did not include rare mutations in high-penetrance genes. DNA sequencing analysis is required to detect these mutations, but was not performed in the REDUCE study. Future studies on assessment of inherited risk should include common PCa risk-associated SNPs, high-penetrance genes associated with PCa risk, as well as FH. 
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